Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders: 2015-2024

Historic Net Income towards Common Stockholders for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$61.0 million.

  • Insight Molecular Diagnostics' Net Income towards Common Stockholders rose 19.56% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 39.68%. This contributed to the annual value of -$61.0 million for FY2024, which is 1986.16% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Net Income towards Common Stockholders of -$61.0 million as of FY2024, which was down 1,986.16% from -$2.9 million recorded in FY2023.
  • In the past 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders registered a high of -$2.9 million during FY2023, and its lowest value of -$73.4 million during FY2022.
  • Over the past 3 years, Insight Molecular Diagnostics' median Net Income towards Common Stockholders value was -$61.0 million (recorded in 2024), while the average stood at -$45.8 million.
  • In the last 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders soared by 96.01% in 2023 and then plummeted by 1,986.16% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders (Yearly) stood at -$29.9 million in 2020, then plummeted by 114.47% to -$64.1 million in 2021, then declined by 14.55% to -$73.4 million in 2022, then skyrocketed by 96.01% to -$2.9 million in 2023, then slumped by 1,986.16% to -$61.0 million in 2024.